New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
07:59 EDTOHRPOhr Pharmaceutical negative report was misleading, says Brean Capital
Brean Capital believes last week's negative report on Ohr Pharmaceuticals was misleading. The firm believes its squalamine eye drops will be effective and expects the company to enter a joint venture to further develop it trodusquemine drug for yet undisclosed new indications. Shares are Buy rated with a $21 price target.
News For OHRP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
09:06 EDTOHRPOhr Pharmaceutical to hold a meeting
Subscribe for More Information
October 20, 2014
07:25 EDTOHRPOhr Pharmaceutical announces positive data on OHR-102 IMPACT study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use